Everything tagged "oncology" across the TickerSpark archives.
BeOne Medicines is delivering strong oncology growth, led by BRUKINSA and expanding TEVIMBRA sales. The stock earns a Buy, but a premium valuation and product concentration keep the risk profile elevated.
Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Corcept has a strong commercial base, a newly approved oncology product, and raised 2026 guidance, but the stock still screens as expensive. The report lands on a Hold as earnings pressure and execution risk offset the long-term growth story.
Summit Therapeutics is a high-risk, high-upside oncology story built around ivonescimab, with positive Phase III data and an FDA review underway. The stock looks attractive for investors willing to accept binary regulatory risk in exchange for platform-scale potential.
AstraZeneca combines durable large-cap biopharma scale with broad-based growth across oncology, rare disease, and respiratory. The report rates AZN a Buy, with valuation the main debate and fair value anchored at $215.
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Medpace is delivering fast revenue growth, strong backlog, and net cash, but the stock already prices in a lot of good news. The report leans constructive, with a selective Buy on pullbacks rather than an aggressive chase.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime